Recent blog posts
Bristol Myers Squibb Reports KRYSTAL-12 Study Success with KRAZATI (Adagrasib) Halting Advanced KRASG12C-Mutant NSCLC Progression
Latest Hotspot
3 min read
Bristol Myers Squibb Reports KRYSTAL-12 Study Success with KRAZATI (Adagrasib) Halting Advanced KRASG12C-Mutant NSCLC Progression
3 April 2024
Bristol Myers Squibb Reveals Key Outcomes from KRYSTAL-12 Study on KRAZATI (adagrasib) Demonstrating Main Goal of Halting Disease Progress in Advanced KRASG12C-Altered Non-Small Cell Lung Cancer.
Read →
EU Approves Merck's KEYTRUDA® for Initial and Adjuvant Treatment in High-Risk NSCLC
Latest Hotspot
3 min read
EU Approves Merck's KEYTRUDA® for Initial and Adjuvant Treatment in High-Risk NSCLC
3 April 2024
The EU Commission has approved the use of Merck's drug KEYTRUDA® (pembrolizumab) in combination with chemotherapy as a first treatment.
Read →
Promising Phase 1B Trial Results of VRON-0200 in Chronic Hepatitis B Premiered at APASL 2024
Latest Hotspot
3 min read
Promising Phase 1B Trial Results of VRON-0200 in Chronic Hepatitis B Premiered at APASL 2024
3 April 2024
Encouraging initial human trial Phase 1B results for VRON-0200, an innovative checkpoint modifier for Chronic Hepatitis B, were showcased as a late-breaking entry at the APASL 2024 Global Liver Conference.
Read →
Biond Biologics introduces revolutionary anti-ILT3 antibody BND-35, aimed at altering the tumor microenvironment, at 2024 AACR Meeting
Latest Hotspot
3 min read
Biond Biologics introduces revolutionary anti-ILT3 antibody BND-35, aimed at altering the tumor microenvironment, at 2024 AACR Meeting
3 April 2024
Biond Biologics reveals at the 2024 AACR Annual Meeting, the introduction of their pioneering anti-ILT3 antibody, BND-35, designed to transform the tumor microenvironment.
Read →
REGENXBIO Study in The Lancet: Single-Dose Gene Therapy ABBV-RGX-314 for Wet AMD
Latest Hotspot
3 min read
REGENXBIO Study in The Lancet: Single-Dose Gene Therapy ABBV-RGX-314 for Wet AMD
3 April 2024
REGENXBIO Reveals Study in The Lancet on Initial Trial for Single-Dose Gene Therapy ABBV-RGX-314 Targeting Wet Age-Related Macular Degeneration.
Read →
Neurocrine Initiates Phase I Trial of VMAT2 Inhibitor NBI-1065890
Latest Hotspot
2 min read
Neurocrine Initiates Phase I Trial of VMAT2 Inhibitor NBI-1065890
2 April 2024
Neurocrine Biosciences Launches Early-Stage Trial for New VMAT2 Blocker, NBI-1065890, in Adult Participants.
Read →
Gilead-Xilio Ink Deal on IL-12 Oncology Project
Latest Hotspot
3 min read
Gilead-Xilio Ink Deal on IL-12 Oncology Project
2 April 2024
Gilead and Xilio have entered into a unique licensing deal dedicated to the development of an oncology-targeted IL-12 initiative.
Read →
Ironwood Pharma's Phase 2 STARGAZE Study Shows Promise for Apraglutide in Treatment-Resistant GI aGVHD
Latest Hotspot
3 min read
Ironwood Pharma's Phase 2 STARGAZE Study Shows Promise for Apraglutide in Treatment-Resistant GI aGVHD
2 April 2024
Ironwood Pharma Reveals Encouraging Outcomes in Phase 2 STARGAZE Study for Apraglutide Treating GI aGVHD Unresponsive to Steroids.
Read →
Avalo Raises $185M for IL-1β Antibody Through Private Funding
Latest Hotspot
4 min read
Avalo Raises $185M for IL-1β Antibody Through Private Funding
2 April 2024
Avalo secures IL-1β monoclonal antibody and reveals plans for a private investment round potentially reaching $185M.
Read →
Vafseo Pill Approved for Adult Dialysis-Related Anemia in the US
Latest Hotspot
3 min read
Vafseo Pill Approved for Adult Dialysis-Related Anemia in the US
2 April 2024
Akebia Therapeutics Granted US Regulatory Clearance for Vafseo (vadadustat) Pills, a New Therapy for Adult Anemia Linked to Long-term Renal Failure in Dialysis Patients.
Read →
Viking Therapeutics Announces Results from First Human Trial of Oral GLP-1/GIP Dual Agonist VK2735
Latest Hotspot
4 min read
Viking Therapeutics Announces Results from First Human Trial of Oral GLP-1/GIP Dual Agonist VK2735
2 April 2024
Viking Therapeutics Reports Outcomes of Initial Human Study for Oral Pill Version of Combined GLP-1/GIP Agonist VK2735.
Read →
TiumBio Files for Phase 1b Trial of Long-Lasting Factor VII TU7710 in Hemophilia A/B Patients
Latest Hotspot
3 min read
TiumBio Files for Phase 1b Trial of Long-Lasting Factor VII TU7710 in Hemophilia A/B Patients
2 April 2024
TiumBio Lodges Application for Phase 1b Study of Prolonged-Effect Factor VII Agent TU7710 in Subjects with Hemophilia A/B.
Read →